← Leaderboards
Patrick Joseph Roberts
G1 Therapeutics, Inc.
$647,891
Attributed
$1,295,781
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $522.4K · FY2013–15$1M$750K$500K$250K$0
'13
'14
'15
Funding mix
By agency
NIH$1,295,781 · 2
By mechanism
R44$1,135,945 · 1
R43$159,836 · 1
Top collaborators
- Jay Copeland Strum4 shared
Most similar at G1 Therapeutics, Inc.
Same institution · by research overlap
- Jay Copeland Strum$3,647,891
- John S Chant$692,326
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAlpha-ThalassemiaAttenuatedBaseBlood PlateletsBone MarrowBone PainBoxingCancer EtiologyCancer ModelCancer PatientCancer TherapyCanis FamiliarisCell CycleCell Cycle ArrestCell LineageCellsCell SurvivalCessation Of LifeChemoprotectionChemotherapeutic AgentChemotherapyChemotherapy-Oncologic ProcedureAcute
Grant awards (4)
Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio$522,431
R44 · FY2015 · CA
Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio$462,399
R44 · FY2014 · CA
Development of CDK4/6 Inhibitors as Novel Renal Protectants$159,836
R43 · FY2013 · DK
Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio$151,115
R44 · FY2013 · CA